{"nctId":"NCT00451958","briefTitle":"A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy","startDateStruct":{"date":"2007-03"},"conditions":["Prostate Cancer"],"count":386,"armGroups":[{"label":"Degarelix 80 mg / Degarelix 80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix 80 mg / Degarelix 80 mg"]},{"label":"Degarelix 160 mg / Degarelix 160 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Degarelix 160 mg / Degarelix 160 mg"]},{"label":"Leuprolide 7.5 mg / Degarelix 80 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Leuprolide 7.5 mg / Degarelix 80 mg"]},{"label":"Leuprolide 7.5 mg / Degarelix 160 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Leuprolide 7.5 mg / Degarelix 160 mg"]}],"interventions":[{"name":"Degarelix 80 mg / Degarelix 80 mg","otherNames":["Firmagon"]},{"name":"Degarelix 160 mg / Degarelix 160 mg","otherNames":["Firmagon"]},{"name":"Leuprolide 7.5 mg / Degarelix 80 mg","otherNames":["Firmagon","Lupron"]},{"name":"Leuprolide 7.5 mg / Degarelix 160 mg","otherNames":["Firmagon","Lupron"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion/Exclusion Criteria:\n\n* Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.\n* Signed informed consent\n* The patients must have completed the FE 200486 CS21 Study.","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Markedly Abnormal Values in Vital Signs and Body Weight","description":"This outcome measure included incidence of markedly abnormal changes in blood pressure (systolic and diastolic), pulse, and body weight. The table presents the number of participants with normal baseline (from main CS21 study, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Markedly Abnormal Values in Safety Laboratory Variables","description":"This outcome measure included incidence of markedly abnormal changes in safety laboratory values. The table presents the number of participants with normal baseline (from main CS21 trial, NCT00295750) and at least one post-baseline markedly abnormal value during CS21A. Only the laboratory variables that had at least five percentages of participants in either group with abnormal value are presented, more variables were included in the study. ULN=Upper limit of normal.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"22","spread":null},{"groupId":"OG003","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"9","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"9","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With no Prostate-specific Antigen (PSA) Progression","description":"PSA progression was defined as two consecutive increases of 50%, and at least 5 ng/mL, compared to nadir (obtained in either CS21, NCT00295750, or CS21A). The figures below present the percentage of participants with no PSA progression at each of the selected time points (there were more time points in the study) along with corresponding 95% confidence intervals (CI).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"99.5","spread":null},{"groupId":"OG002","value":"98.6","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.1","spread":null},{"groupId":"OG001","value":"85.8","spread":null},{"groupId":"OG002","value":"82.6","spread":null},{"groupId":"OG003","value":"87.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"58.7","spread":null},{"groupId":"OG002","value":"50.7","spread":null},{"groupId":"OG003","value":"73.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Testosterone Level Maintained at <=0.5 ng/mL From Day 28 in CS21 and Onwards","description":"The results below present the percentage of participants of having testosterone \\<=0.5 ng/mL at each of the selected time points (there were more time points in the study) from Day 28 in CS21 (NCT00295750) until the end of the CS21A study.\n\nIn all treatment groups approximately 3% per year of the participants had at least one testosterone \\>0.5 ng/mL during the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"98.6","spread":null},{"groupId":"OG003","value":"97.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.2","spread":null},{"groupId":"OG001","value":"98.3","spread":null},{"groupId":"OG002","value":"97.","spread":null},{"groupId":"OG003","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.0","spread":null},{"groupId":"OG001","value":"87.7","spread":null},{"groupId":"OG002","value":"84.1","spread":null},{"groupId":"OG003","value":"88.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Levels of Testosterone From the Time of Switch From Leuprolide to Degarelix up to Day 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":null},{"groupId":"OG001","value":"0.074","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.084","spread":null},{"groupId":"OG001","value":"0.068","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.076","spread":null},{"groupId":"OG001","value":"0.066","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.085","spread":null},{"groupId":"OG001","value":"0.073","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.074","spread":null},{"groupId":"OG001","value":"0.074","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.080","spread":null},{"groupId":"OG001","value":"0.077","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Levels of PSA From the Time of Switch From Leuprolide to Degarelix to Day 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Levels of Luteinizing Hormone (LH) From the Time of Switch From Leuprolide to Degarelix to Day 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":null},{"groupId":"OG001","value":"0.035","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":null},{"groupId":"OG001","value":"0.035","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":null},{"groupId":"OG001","value":"0.035","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":null},{"groupId":"OG001","value":"0.035","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":null},{"groupId":"OG001","value":"0.035","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.035","spread":null},{"groupId":"OG001","value":"0.035","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Levels of Follicle Stimulating Hormone (FSH) From the Time of Switch From Leuprolide to Degarelix to Day 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":null},{"groupId":"OG001","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":null},{"groupId":"OG001","value":"1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"1.55","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":43,"n":207},"commonTop":["Injection site pain","Hot flush","Injection site erythema","Weight increased","Weight decreased"]}}}